From the Department of Emergency Medicine (B.W.F., E.I., D.C., D.Z., M.M., P.E.B., E.J.G.) and Medical College (A.C.), Albert Einstein College of Medicine, Montefiore, Bronx; Departments of Neurology and Population Health (M.T.M.), NYU Langone Health, New York; and Pharmacy Department (C.S., E.Z.), Montefiore, Bronx, NY.
Neurology. 2021 May 4;96(18):e2323-e2331. doi: 10.1212/WNL.0000000000011822. Epub 2021 Mar 24.
To determine whether IV metoclopramide 20 mg + diphenhydramine 25 mg (M + D) was more efficacious than IV placebo for acute moderate or severe posttraumatic headache in the emergency room.
We conducted this randomized, double-blind, placebo-controlled, parallel-group study in 2 urban emergency departments (EDs). Participants who experienced head trauma and presented to our EDs within 10 days with a headache fulfilling criteria for acute posttraumatic headache were included. We randomized participants in a 1:1 ratio to M + D or placebo. Participants, caregivers, and outcome assessors were blinded to assignment. The primary outcome was improvement in pain on a scale of 0 to 10 between baseline and 1 hour after treatment.
This study was completed between August 2017 and March 2020. We screened 414 patients for participation and randomized 160: 81 to M + D and 79 to placebo. Baseline characteristics were comparable between the groups. All enrolled participants provided primary outcome data. Patients receiving placebo reported mean improvement of 3.8 (SD 2.6), while those receiving M + D improved by 5.2 (SD 2.3), for a difference favoring metoclopramide of 1.4 (95% confidence interval [CI] 0.7-2.2, < 0.01). Adverse events were reported by 35 of 81 (43%) patients who received metoclopramide and 22 of 79 (28%) of patients who received placebo (95% CI 1-30 for difference of 15%, = 0.04).
M + D was more efficacious than placebo with regard to relief of posttraumatic headache in the ED.
ClinicalTrials.gov Identifier: NCT03220958.
This study provides Class I evidence that for patients with acute moderate or severe posttraumatic headache, IV M + D significantly improved pain compared to placebo.
在急诊科,比较 IV 甲氧氯普胺 20mg+苯海拉明 25mg(M+D)与 IV 安慰剂治疗急性中度或重度创伤后头痛的疗效。
我们在 2 家市区急诊科进行了这项随机、双盲、安慰剂对照、平行组研究。参与者在创伤后 10 天内出现头痛,满足急性创伤后头痛的标准,入组本研究。我们以 1:1 的比例将参与者随机分配至 M+D 或安慰剂组。参与者、护理人员和结局评估人员对分组情况设盲。主要结局为治疗后 1 小时与基线相比,疼痛评分(0-10 分)的改善情况。
这项研究于 2017 年 8 月至 2020 年 3 月进行。我们共筛选了 414 名参与者,其中 160 名入组:81 名接受 M+D,79 名接受安慰剂。两组基线特征相当。所有入组的参与者均提供了主要结局数据。接受安慰剂的患者报告平均改善 3.8(标准差 2.6),而接受 M+D 的患者改善 5.2(标准差 2.3),M+D 组更优,差值为 1.4(95%置信区间[CI] 0.7-2.2,<0.01)。81 名接受甲氧氯普胺的患者中有 35 名(43%)和 79 名接受安慰剂的患者中有 22 名(28%)报告了不良事件(95%CI 1-30,差值为 15%,=0.04)。
与安慰剂相比,M+D 更能有效缓解急诊科创伤后头痛。
ClinicalTrials.gov 标识符:NCT03220958。
本研究提供了 I 级证据,表明对于急性中度或重度创伤后头痛的患者,与安慰剂相比,IV M+D 可显著改善疼痛。